Literature DB >> 28457906

Widespread cortical demyelination of both hemispheres can be induced by injection of pro-inflammatory cytokines via an implanted catheter in the cortex of MOG-immunized rats.

Muammer Üçal1, Michaela Tanja Haindl2, Milena Z Adzemovic3, Johannes Strasser2, Lisa Theisl2, Manuel Zeitelhofer4, Klaus Kraitsy1, Stefan Ropele2, Ute Schäfer1, Franz Fazekas2, Sonja Hochmeister5.   

Abstract

Cortical demyelination is a common finding in patients with chronic multiple sclerosis (MS) and contributes to disease progression and overall disability. The exact pathomechanism that leads to cortical lesions is not clear. Research is limited by the fact that standard animal models of multiple sclerosis do not commonly affect the cortex, or if they do in some variants, the cortical demyelination is rather sparse and already remyelinated within a few days. In an attempt to overcome these limitations we implanted a tissue-compatible catheter into the cortex of Dark Agouti rats. After 14days the rats were immunized with 5μg myelin oligodendrocyte glycoprotein (MOG) in incomplete Freund's Adjuvant, which did not cause any clinical signs but animals developed a stable anti-MOG antibody titer. Then the animals received an injection of proinflammatory cytokines through the catheter. This led to a demyelination of cortical and subcortical areas starting from day 1 in a cone-like pattern spreading from the catheter area towards the subarachnoid space. On day 3 cortical demyelination already expanded to the contralateral hemisphere and reached its peak between days 9-15 after cytokine injection with a widespread demyelination of cortical and subcortical areas of both hemispheres. Clinically the animals showed only discrete signs of fatigue and recovered completely after day 15. Even on day 30 we still were able to detect demyelination in subpial and intracortical areas along with areas of partial and complete remyelination. Loss of cortical myelin was accompanied with marked microglia activation. A second injection of cytokines through the catheter on day 30 led to a second demyelination phase with the same symptoms, but again no detectable motor dysfunction. Suffering of the animals appeared minor compared to standard Experimental Autoimmune Encephalomyelitis and therefore, even long-term observation and repeated demyelination phases seem ethically acceptable.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal model; Cortical demyelination; Neuroimmunology; Neuroinflammation; Progressive multiple sclerosis

Mesh:

Substances:

Year:  2017        PMID: 28457906     DOI: 10.1016/j.expneurol.2017.04.014

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  4 in total

1.  Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.

Authors:  Liqin Yang; Haiqing Li; Wei Xia; Chao Quan; Lei Zhou; Daoying Geng; Yuxin Li
Journal:  Eur Radiol       Date:  2019-11-20       Impact factor: 5.315

2.  miRNA profile is altered in a modified EAE mouse model of multiple sclerosis featuring cortical lesions.

Authors:  Nicola S Orefice; Owein Guillemot-Legris; Mireille Alhouayek; Giulio G Muccioli; Rosanna Capasso; Pauline Bottemanne; Philippe Hantraye; Michele Caraglia; Giuseppe Orefice
Journal:  Elife       Date:  2020-09-17       Impact factor: 8.140

3.  Persistent elevation of intrathecal pro-inflammatory cytokines leads to multiple sclerosis-like cortical demyelination and neurodegeneration.

Authors:  Rachel E James; Renee Schalks; Eleanor Browne; Ioanna Eleftheriadou; Carmen Picon Munoz; Nicholas D Mazarakis; Richard Reynolds
Journal:  Acta Neuropathol Commun       Date:  2020-05-12       Impact factor: 7.801

4.  Anti-CD20 treatment effectively attenuates cortical pathology in a rat model of widespread cortical demyelination.

Authors:  Michaela T Haindl; Muammer Üçal; Benjamin Klaus; Lennart Tögl; Jana Dohrmann; Milena Z Adzemovic; Christian Enzinger; Sonja Hochmeister
Journal:  J Neuroinflammation       Date:  2021-06-15       Impact factor: 8.322

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.